BRPI0908942A2 - Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos - Google Patents

Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos

Info

Publication number
BRPI0908942A2
BRPI0908942A2 BRPI0908942A BRPI0908942A BRPI0908942A2 BR PI0908942 A2 BRPI0908942 A2 BR PI0908942A2 BR PI0908942 A BRPI0908942 A BR PI0908942A BR PI0908942 A BRPI0908942 A BR PI0908942A BR PI0908942 A2 BRPI0908942 A2 BR PI0908942A2
Authority
BR
Brazil
Prior art keywords
weakly basic
lpt
delivery systems
organic acids
drug delivery
Prior art date
Application number
BRPI0908942A
Other languages
English (en)
Inventor
Venkatesh Gopi
Lai Jin-Wang
H Vyas Nehal
Purohit Vivek
Original Assignee
Eurand Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41063296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908942(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand Inc filed Critical Eurand Inc
Publication of BRPI0908942A2 publication Critical patent/BRPI0908942A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SISTEMAS DE DISTRIBUIÇÃO DE FÁRMACOS COMPREENDENDO FÁRMACOS FRACAMENTE BÁSICOS E ÁCIDOS ORGÂNICOS. A presente invenção é dirigida a composições farmacêuticas, e a métodos de fabricação dessas composições, em que as composições compreendem uma pluralidade de partículas LPT e LR, em que: cada uma das partículas LPT compreende um núcleo revestido com uma camada LPT; o núcleo compreende um fármaco fracamente básico e pouco solúvel e um ácido orgânico farmaceuticamente aceitável separados um do outro por uma camada LS; cada uma das partículas LR compreende o fármaco fracamente básico e pouco solúvel, e libera pelo menos cerca de 80% por peso do fármaco fracamente básico e pouco solúvel em cerca de 5 minutos quando é efetuado o teste de dissolução usando a metodologia de dissolução da Farmacopéia dos Estados Unidos (USP) (Aparato 2 - pás @ 50 RPM e um meio de dissolução em dois estágios a 37°C (primeiras 2 horas em HCl 0,1 N, seguido de teste em um tampão a pH 6.8).
BRPI0908942A 2008-03-12 2009-03-11 Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos BRPI0908942A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3584008P 2008-03-12 2008-03-12
US12/209,285 US8133506B2 (en) 2008-03-12 2008-09-12 Drug delivery systems comprising weakly basic drugs and organic acids
PCT/US2009/036787 WO2009114606A1 (en) 2008-03-12 2009-03-11 Drug delivery systems comprising weakly basic drugs and organic acids

Publications (1)

Publication Number Publication Date
BRPI0908942A2 true BRPI0908942A2 (pt) 2017-09-19

Family

ID=41063296

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908942A BRPI0908942A2 (pt) 2008-03-12 2009-03-11 Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos

Country Status (24)

Country Link
US (1) US8133506B2 (pt)
EP (1) EP2265261B1 (pt)
JP (1) JP5634882B2 (pt)
KR (1) KR101660927B1 (pt)
CN (1) CN101977593B (pt)
AR (1) AR071562A1 (pt)
AU (1) AU2009223019C1 (pt)
BR (1) BRPI0908942A2 (pt)
CA (1) CA2718257C (pt)
CL (1) CL2009000598A1 (pt)
DK (1) DK2265261T3 (pt)
ES (1) ES2590479T3 (pt)
HU (1) HUE029680T2 (pt)
IL (1) IL208089A0 (pt)
MX (1) MX2010010052A (pt)
NZ (1) NZ587897A (pt)
PL (1) PL2265261T3 (pt)
PT (1) PT2265261T (pt)
RU (1) RU2504362C2 (pt)
SA (1) SA109300166B1 (pt)
SG (1) SG10201405929UA (pt)
TW (1) TWI440480B (pt)
WO (1) WO2009114606A1 (pt)
ZA (1) ZA201006557B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090082A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
RU2515972C2 (ru) 2008-06-11 2014-05-20 Дженентек, Инк. Диазакарбазолы и способы применения
KR20120022895A (ko) * 2009-04-09 2012-03-12 엘커메스 파마 아일랜드 리미티드 약물 전달 조성물
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
BR112012012999A2 (pt) 2009-11-30 2019-04-02 Aptalis Pharmatech Inc Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt)
WO2011082426A1 (en) * 2010-01-04 2011-07-07 Eurand, Inc. Controlled release compositions comprising meclizine or related piperazine derivatives
US20120164233A1 (en) * 2010-07-30 2012-06-28 Ranbaxy Laboratories Limited Pulsatile release pharmaceutical formulation of dexlansoprazole
PE20131101A1 (es) * 2010-08-13 2013-09-23 Euro Celtique Sa Formulaciones estables al almacenamiento de oxicodona y naloxona
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
WO2012075455A2 (en) 2010-12-02 2012-06-07 Aptalis Pharmatech, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
KR101458334B1 (ko) * 2010-12-23 2014-11-04 퍼듀 퍼머 엘피 탬퍼 저항성 고체 경구 투여 형태
LT2861236T (lt) * 2012-06-15 2019-09-25 Pharmathen S.A. Farmacinė kompozicija, turinti fosforą rišančio polimero
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6392355B2 (ja) * 2013-09-13 2018-09-19 アール．ピー．シェーラー テクノロジーズ、エルエルシー ペレット包含錠剤
CN105797162B (zh) * 2014-12-31 2022-10-25 昆明积大制药股份有限公司 药用辅料表面改性方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
EP0225085A1 (en) * 1985-11-13 1987-06-10 ELAN CORPORATION, Plc Controlled absorption pharmaceutical formulation
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
NZ242806A (en) * 1991-05-20 1994-01-26 Marion Laboratories Inc Multi-layered acid-containing coated drug beads.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
AU741992B2 (en) * 1998-03-06 2001-12-13 Adare Pharmaceuticals S.R.L. Fast disintegrating tablets
US6602521B1 (en) * 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
US6936275B2 (en) * 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
CA2395974A1 (en) * 2000-01-20 2001-07-26 Suggy S. Chrai Multi-step drug dosage forms
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
PL366150A1 (en) 2000-10-30 2005-01-24 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
EP1491185B1 (en) * 2002-03-14 2009-05-27 Medrx Co., Ltd. External medicine for wounds
US7939102B2 (en) 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
WO2004096182A1 (en) 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Extended release matrix tablets of carvedilol
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
WO2005065640A1 (en) 2004-01-06 2005-07-21 Panacea Biotec Ltd. Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions
WO2005077341A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Orally disintegrating pharmaceutical compositions of ondansetron
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
WO2005105045A1 (ja) * 2004-04-30 2005-11-10 Astellas Pharma Inc. 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
US8512751B2 (en) * 2004-12-20 2013-08-20 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
HU227490B1 (en) * 2005-08-26 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sustained release pharmaceutical preparation containing carvedilol
WO2007090082A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
BRPI0716196A2 (pt) * 2006-08-31 2013-11-12 Eurand Inc Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.

Also Published As

Publication number Publication date
MX2010010052A (es) 2011-01-25
CA2718257C (en) 2016-07-19
TWI440480B (zh) 2014-06-11
JP5634882B2 (ja) 2014-12-03
CN101977593B (zh) 2014-08-06
US8133506B2 (en) 2012-03-13
RU2504362C2 (ru) 2014-01-20
AR071562A1 (es) 2010-06-30
KR20100129756A (ko) 2010-12-09
AU2009223019B2 (en) 2013-10-03
EP2265261B1 (en) 2016-07-06
AU2009223019C1 (en) 2015-05-07
SA109300166B1 (ar) 2013-07-04
ES2590479T3 (es) 2016-11-22
NZ587897A (en) 2012-10-26
TW200942273A (en) 2009-10-16
JP2011513498A (ja) 2011-04-28
EP2265261A4 (en) 2013-07-03
CL2009000598A1 (es) 2009-08-21
CA2718257A1 (en) 2009-09-17
ZA201006557B (en) 2011-12-28
CN101977593A (zh) 2011-02-16
DK2265261T3 (en) 2016-10-03
PT2265261T (pt) 2016-09-14
SG10201405929UA (en) 2014-11-27
US20090232885A1 (en) 2009-09-17
IL208089A0 (en) 2010-12-30
KR101660927B1 (ko) 2016-09-28
PL2265261T3 (pl) 2017-01-31
AU2009223019A1 (en) 2009-09-17
EP2265261A1 (en) 2010-12-29
HUE029680T2 (en) 2017-02-28
RU2010141726A (ru) 2012-04-20
WO2009114606A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
BRPI0908942A2 (pt) Sistemas de distribuição de fármacos compreendendo fármacos fracamente básicos e ácidos orgânicos
Haji et al. TNF-α-mediated anxiety in a mouse model of multiple sclerosis
US9901568B2 (en) Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
EP3708156A1 (en) Novel anti-infective strategy against influenza virus and s. aureus coinfections
Le Marec et al. Chronic and intermittent morphine treatment differently regulates opioid and dopamine systems: a role in locomotor sensitization
BRPI0716436B8 (pt) sistema de liberação controlada e método para fabricação do mesmo
CY1119839T1 (el) Στερεες μορφες δοσεως μπενταμουστινης
BR112013003581A2 (pt) formulação farmacêutica ou nutracêutica gastro resistente que compreende um ou mais sais do ácido algínico
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
CN103415286A (zh) 用于治疗疼痛的化合物和方法
EA201400972A1 (ru) Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения
JP2015519329A5 (pt)
JP2010518086A5 (pt)
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
Kotagale et al. Chronic agmatine treatment prevents behavioral manifestations of nicotine withdrawal in mice
Cuppoletti et al. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors
Wei et al. Role of gabapentin in preventing fentanyl-and morphine-withdrawal-induced hyperalgesia in rats
GT200900089A (es) Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine
JP2012533595A5 (pt)
HRP20220856T1 (hr) Pripravci ugodna okusa uključujući natrijev fenilbutirat i njihove uporabe

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: EURAND, INC. (US)